公开(公告)号：US20230011234A1

公开(公告)日：2023-01-12

申请号：US17761838

申请日：2020-09-20

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Andrei Borisovich ULITIN ,  Aleksey Vladimirovich KONONOV ,  Sergei Andreevich AGEEV ,  Aleksandr Andreevich GORDEEV ,  Elena Vladimirovna VINOGRADOVA ,  Stanislav Rudolfovich EVDOKIMOV ,  Aleksandra Pavlovna SHMAKOVA ,  Ivan Vladimirovich MITROSHIN ,  Dmitry Valentinovich MOROZOV

IPC: C07K14/54 ,  C07K14/715 ,  A61P35/00

Abstract: The present invention relates to an immunocytokine comprising an heterodimeric protein complex based on IL-15/IL-15Rα, and to use thereof as a therapeutic agent, in particular as an agent for the treatment of cancer and an autoimmune disease. The present invention further relates to an immunocytokine comprising a heterodimeric protein complex based on an IL-15/IL-15Rα and an immunomodulatory antibody, and to use thereof as a therapeutic agent, in particular as an agent for the treatment of cancer and an autoimmune disease.

公开(公告)号：US20220372127A1

公开(公告)日：2022-11-24

申请号：US17599380

申请日：2020-04-02

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Ekaterina Valerevna CHERNIAEVA ,  Ekaterina Aleksandrovna LOMKOVA ,  Antonina Vasilevna ARTEMEVA ,  Anna Viktorovna EREMEEVA ,  Roman Alekseevich IVANOV ,  Anastasiya Mikhajlovna RYAKHOVSKAYA ,  Viktoriia Olegovna SHITIKOVA ,  Aleksandr Olegovich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: C07K16/24 ,  A61K47/22 ,  A61K47/26 ,  A61K47/12 ,  A61K47/10 ,  A61P19/02

Abstract: The present disclosure relates to aqueous compositions for anti-IL17a antibodies, and more particularly to aqueous compositions for anti-IL17a antibodies with a VHH variable domain and a VL variable domain, and can be used as a medicinal agent for treating IL-17A-mediated diseases.

公开(公告)号：US20220017896A1

公开(公告)日：2022-01-20

申请号：US17296629

申请日：2019-11-26

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Konstantin Viktorovich SEVERINOV ,  Sergey Anatolevich SHMAKOV ,  Daria Nikolaevna ARTAMONOVA ,  Ignatiy Igorevich GORYANIN ,  Olga Sergeevna MUSHAROVA ,  Iuliia Valerevna PISKUNOVA ,  Iana Vitalevna FEDOROVA ,  Tatyana Igorevna ZYUBKO ,  Mikhail Alekseevich KHODORKOVSKIY ,  Georgii Evgenevich POBEGALOV ,  Anatolii Nikolaevich ARSENIEV ,  Polina Anatolevna SELKOVA ,  Aleksandra Andreevna VASILEVA ,  Tatiana Olegovna ARTAMONOVA ,  Marina Viktorovna ABRAMOVA

IPC: C12N15/11 ,  C12N9/22

Abstract: The present invention describes a novel bacterial nuclease of the CRISPR-Cas9 system from the bacterium Defluviimonas sp. 20V17, as well as the use thereof to form strictly specific double-strand breaks in a DNA molecule. This nuclease has unusual properties and may be used as a tool for introducing modifications at strictly defined sites in the genomic DNA sequence of unicellular or multicellular organisms. Thus, the versatility of the available CRISPR-Cas9 systems is increased, which will enable the use of Cas9 nucleases from various organisms for cutting genomic or plasmid DNA in a larger number of specific sites and specific conditions.

公开(公告)号：US20200339544A1

公开(公告)日：2020-10-29

申请号：US16753847

申请日：2018-10-05

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Kirill Vadimovich ZAVIALOV ,  Svetlana Leonidovna GORBUNOVA ,  Artsiom Evgenievich SHEKHAUTSOU ,  Mariia Andreevna KASATKINA ,  Daria Dmitrievna BEKETOVA ,  Natalia Vladimirovna KOZHEMYAKINA ,  Kirill Igorevich KULISH ,  Elena Aleksandrovna MAKSIMENKO ,  Marina Viktorovna MELESHINA ,  Olga Anatolevna MELCHAEVA ,  Aleksei Leonidovich MINDICH ,  Dmitry Valentinovich MOROZOV ,  Aleksandra Vladimirovna POPKOVA ,  Ilia Alexeevich SMETANIN ,  Sergey Aleksandrovich SILONOV ,  Iaroslavna Alexandrovna SOLDATOVA ,  Georgii Viktorovich IAKOBSON

IPC: C07D403/06 ,  C07D239/42 ,  C07D213/74 ,  C07D413/10 ,  C07D401/06 ,  A61P35/00

Abstract: The present invention relates to novel compounds of formula I, or pharmaceutically acceptable salts, solvates or stereoisomers thereof, also to a pharmaceutical composition, a method for inhibiting biological activity of epidermal growth factor receptor (EGFR), a method for treating diseases or disorders mediated by the activation of EGFR and use of the present compounds or the present pharmaceutical composition for the treatment of a disease or disorder mediated by the activation of EGFR.

公开(公告)号：US20200031952A1

公开(公告)日：2020-01-30

申请号：US16564148

申请日：2019-09-09

Applicant: CLOSED JOINT STOCK COMPANY "BIOCAD"

Inventor： Andrey Borisovich ULITIN ,  Stanislav Rudolfovich EVDOKIMOV ,  Valeriy Vladimirovich SOLOVIEV ,  Yulia Sergeevna CHERNYKH ,  Olga Vladimirovna GONCHAROVA ,  Dmitriy Valerievich KORZHAVIN ,  Tatyana Veniaminovna CHERNOVSKAYA ,  Timofey Aleksandrovich NEMANKIN ,  Roman Alexeevich IVANOV ,  Dmitriy Valentinovich MOROZOV ,  Victoria Mikhailovna EKIMOVA ,  Ekaterina Vladimirovna SOFRONOVA ,  Yakov Yurevich USTYUGOV

IPC: C07K16/46 ,  A61K39/395 ,  A61K45/06 ,  C07K16/24

Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.

公开(公告)号：US10442857B2

公开(公告)日：2019-10-15

申请号：US15254190

申请日：2016-09-01

Applicant: CLOSED JOINT STOCK COMPANY “BIOCAD”

Inventor： Andrey Borisovich Ulitin ,  Stanislav Rudolfovich Evdokimov ,  Valeriy Vladimirovich Soloviev ,  Yulia Sergeevna Chernyh ,  Olga Vladimirovna Goncharova ,  Dmitriy Valerievich Korzhavin ,  Tatyana Veniaminovna Chernovskaya ,  Roman Alexeevich Ivanov ,  Dmitriy Valentinovich Morozov

IPC: A61K39/395 ,  C07K16/24 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention relates to the field of medicine, and specifically to the field of monoclonal antibodies against human IL-17. More specifically, the invention relates to monoclonal antibodies/antagonists of IL-17A, which bind with high affinity to an IL-17 epitope, wherein the antibodies contain amino acid substitutions in hypervariable regions of heavy and light chains. The antibodies according to this invention can be chimeric, humanized or human antibodies or antigen-binding fragments thereof, and can be used as a medicinal agent for treating autoimmune and inflammatory disorders and disorders of cell proliferation and development. The invention also relates to methods for producing said antibodies.

公开(公告)号：US20160151132A1

公开(公告)日：2016-06-02

申请号：US14951949

申请日：2015-11-25

Applicant: Biocad Medical, Inc.

Inventor： Myriam Manai ,  David Giasson ,  Bin Hang

IPC: A61C13/00

CPC classification number: G06F17/50 ,  A61C11/00 ,  A61C13/097 ,  G16H20/40

Abstract: Herein are provided methods, systems, computer-readable media, techniques and processes for occlusion estimation in dental prosthesis design. These include determining a first contact point between antagonist teeth, then simulating motion in order to determine additional contact points. Various of the determined contact points may not be used in the simulated motion, based on the simulated physics. When one or more predetermined stopping criteria have been met, then the contact points may be used to define the relative occlusal positions of antagonists. In some embodiments, sets of teeth in a bridge or crown, e.g., may be simulated as moving separately and a new state for each set of teeth may be determined.

Abstract translation: 这里提供了用于牙科假体设计中的闭塞估计的方法，系统，计算机可读介质，技术和过程。 这些包括确定拮抗剂牙齿之间的第一接触点，然后模拟运动以确定额外的接触点。 基于模拟物理学，可以在模拟运动中使用各种确定的接触点。 当满足一个或多个预定停止标准时，接触点可用于限定拮抗剂的相对咬合位置。 在一些实施例中，桥或冠中的齿组可以被模拟为单独移动，并且可以确定每组齿的新状态。

公开(公告)号：US12173336B2

公开(公告)日：2024-12-24

申请号：US17276016

申请日：2019-09-13

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Dmitriy Aleksandrovich Madera ,  Aleksandr Vladimirovich Karabelskii ,  Roman Alekseevich Ivanov ,  Dmitry Valentinovich Morozov ,  Konstantin Viktorovich Severinov ,  Sergey Anatolevich Shmakov ,  Dmitrii Aleksandrovich Sutormin ,  Georgii Evgenevich Pobegalov ,  Aleksandra Andreevna Vasileva ,  Polina Anatolevna Selkova ,  Anatolii Nikolaevich Arseniev ,  Tatyana Igorevna Zyubko ,  Iana Vitalevna Fedorova

IPC: C12N9/22 ,  C12N15/79

Abstract: The present invention relates to the field of biotechnology, molecular biology and medicine, in particular to nuclease enzyme and use thereof. More specifically, the present invention relates to PaCas9 nuclease enzyme. The invention also relates to a nucleic acid encoding the nuclease, a genetic construct, an expression vector, a delivery vector, which comprise the nucleic acid, a liposome comprising the nuclease or nucleic acid encoding the nuclease, a method for producing a nuclease, methods for delivery, and a host cell comprising a nucleic acid encoding the nuclease.

公开(公告)号：US20230357396A1

公开(公告)日：2023-11-09

申请号：US18103194

申请日：2023-01-30

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Olga Vladimirovna BRITANOVA ,  Mark Aleksandrovic IZRAELSON ,  Sergey Anatolievich LUKYANOV

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2809 ,  A61K39/3955 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to monoclonal antibodies which specifically bind to the TRBV9 family of human T-cell receptors. The invention also relates to a nucleic acid which codes for said antibody or for an antigen-binding fragment thereof, to an expression vector, to a method for producing the antibody, and to the use of said antibody for treating diseases or disorders associated with the family of human T-cell receptors. The invention is directed towards producing antibodies that can be used for eliminating T-cells carrying T-cell receptors of the TRBV9 family, in particular for treating ankylosing spondylitis, coeliac disease, and blood cancers, in the pathogenesis of which T-cell receptors of the TRBV9 family are involved.

公开(公告)号：US20230321220A1

公开(公告)日：2023-10-12

申请号：US18043354

申请日：2021-08-27

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Alexander Vladimirovich PROKOFYEV ,  Pavel Mikhailovich GERSHOVICH ,  Anna Nikolaevna STRELKOVA ,  Natalia Aleksandrovna SPIRINA ,  Diana Aleksandrovna KONDINSKAIA ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12

CPC classification number: A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071 ,  C12N2750/14143 ,  A61K2039/5256

Abstract: The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to a nucleic acid that encodes RBD-S of SARS-CoV-2, to an expression cassette and a vector based thereon, as well as to a recombinant AAV5 (adeno-associated vims serotype 5)-based virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.